Search results
Moderna’s New Flu-COVID Combi mRNA Vaccine Outperforms Separate Shots In Trials
IFLScience· 3 days agoModerna became a household name thanks to the success of its mRNA vaccine against COVID-19. Along...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 1 day agoAnd emergency room visits for COVID rose by 16.2% for the week ending June 1. But hospitalizations...
2-in-1 shot for flu and COVID shows promise in advanced trial
Live Science via Yahoo News· 4 days ago(Notably, newer versions of omicron have now overtaken XBB.1.5, so the new vaccine's effectiveness...
New RSV shots tied to rare nervous system disorder — should you worry?
Live Science via Yahoo News· 1 day agoThere's been some reports of Guillain-Barré syndrome in older adults who got the vaccines. But...
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News· 4 days agoA combination COVID-influenza vaccine is apparently one step closer to hitting the market. Moderna,...
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
NBC Miami· 5 days agoModerna said its combination vaccine targeting Covid and the flu was more effective than existing...
Celebrity doctors promoted Covid vaccine without declaring payments
The Telegraph via Yahoo News· 6 days agoThe pharmaceutical watchdog has been urged to investigate after a string of celebrity doctors took...
Moderna says combination flu, COVID shot succeeds in study
BioPharma Dive via Yahoo Finance· 5 days agoAdvisers to the Food and Drug Administration in March recommended that flu vaccines this year be...
Moderna says its combination COVID and flu vaccine tested better than separate shots
CBS News· 4 days agoModerna announced Monday that its combination COVID and flu vaccine showed positive results in a...
FDA clears GSK's RSV vaccine for adults ages 50-59
United Press International via Yahoo News· 6 days agoThe U.S. Food and Drug Administration on Friday approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the...